pharma · Chronic Lymphocytic Leukemia (CLL) · Relapsed/Refractory B-cell Malignancies · NRIX
Nurix Therapeutics
Nurix Therapeutics patent portfolio — 14 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Founded
- 2012
- Employees
- 350
- Programs
- 9
- Drugs
- 4
- Patents
- 14
Nurix Therapeutics patents
14 pharmaceutical patents indexed for Nurix Therapeutics. 0 expire within 24 months.
Nurix Therapeutics has 14 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12377106
Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK
granted -
US 12234230
Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
granted -
US 12121540
CBL inhibitors and compositions for use in adoptive cell therapy
granted -
US 12091426
Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
granted -
US 12049471
Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
granted -
US 12016860
Combination therapies with Cbl-b inhibitor compounds
granted -
US 11951133
3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
granted -
US 11866442
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
granted -
US 11820781
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
granted -
US 11739101
Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
granted -
US 11530229
Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
granted -
US 11479556
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
granted -
US 11464802
3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
granted -
US 11401267
Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
granted
Frequently asked questions
How many patents does Nurix Therapeutics have?
14 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Nurix Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.